Home » Topics » BioWorld Science

BioWorld Science
RSS

CF-MEV-132 reduces lung damage in rat model of hyperoxia-induced bronchopulmonary dysplasia

Nov. 7, 2018

Corcept Therapeutics enrolling participants in phase III study of relacorilant

Nov. 7, 2018

Enesi and Sementis collaborate on solid dose vaccine development

Nov. 7, 2018

INS-3001 demonstrates efficacy in rat model of vascular calcifications

Nov. 7, 2018

Discovery of new envelope-based antigen that triggers potent humoral responses against HIV-1

Nov. 7, 2018

Deubiquitinase Usp12 is neuroprotective in Huntington's disease neurons

Nov. 7, 2018

YC-6 exhibits safety and tolerability in first-in-human study

Nov. 7, 2018

GlycoMimetics initiates phase III trial of uproleselan in relapsed/refractory AML

Nov. 7, 2018

Fat and fibroblasts

Nov. 7, 2018

New insights into microexon regulation

Nov. 7, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...